Bristol Myers Squibb is ending work on a handful of assets, including an immunology medication that was in two Phase 3 trials ...

The move comes less than a year after the company attempted to save $1.5 billion through the layoff of some 2,200 employees.

Financial discipline remained a priority, with approximately $1.1 billion of the targeted $1.5 billion in savings already realized. The company has identified an additional $2 billion in savings, with ...

U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 150 points on Thursday. The Dow ...

Shares of Bristol-Myers Squibb (NYSE:BMY) traded lower in the premarket on Thursday after the pharma giant beat Street forecasts with its Q4 2024 results, but its 2025 outlook fell short of analysts’ ...

The company also issued a 2025 guidance that fell short of expectations, as some of the company’s older drugs face ...

Bristol Myers Squibb announces $2B in new cost cuts over 3 years, including workforce reductions, following $1.5B cuts in ...

The company disclosed preliminary results in mid January, but it left out important metrics such as earnings per share for the fourth quarter.

Arm Holdings beat estimates for the chip designer's fiscal third quarter but offered in-line guidance. Arm stock fell on the ...